- Home
- ADPT vs MD Comparison
ADPT vs MD Comparison
Compare ADPT & MD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- MD
- Stock Information
- Founded
- ADPT 2009
- MD 1979
- Country
- ADPT United States
- MD United States
- Employees
- ADPT N/A
- MD N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- MD Hospital/Nursing Management
- Sector
- ADPT Health Care
- MD Health Care
- Exchange
- ADPT Nasdaq
- MD Nasdaq
- Market Cap
- ADPT 1.4B
- MD 1.2B
- IPO Year
- ADPT 2019
- MD 1995
- Fundamental
- Price
- ADPT $11.88
- MD $13.78
- Analyst Decision
- ADPT Strong Buy
- MD Buy
- Analyst Count
- ADPT 7
- MD 6
- Target Price
- ADPT $10.57
- MD $16.67
- AVG Volume (30 Days)
- ADPT 2.2M
- MD 671.1K
- Earning Date
- ADPT 07-31-2025
- MD 08-05-2025
- Dividend Yield
- ADPT N/A
- MD N/A
- EPS Growth
- ADPT N/A
- MD N/A
- EPS
- ADPT N/A
- MD N/A
- Revenue
- ADPT $189,527,000.00
- MD $1,976,177,000.00
- Revenue This Year
- ADPT $24.46
- MD N/A
- Revenue Next Year
- ADPT $20.25
- MD $3.26
- P/E Ratio
- ADPT N/A
- MD N/A
- Revenue Growth
- ADPT 8.61
- MD N/A
- 52 Week Low
- ADPT $3.30
- MD $6.62
- 52 Week High
- ADPT $12.43
- MD $17.67
- Technical
- Relative Strength Index (RSI)
- ADPT 63.39
- MD 48.57
- Support Level
- ADPT $11.17
- MD $12.99
- Resistance Level
- ADPT $12.43
- MD $14.66
- Average True Range (ATR)
- ADPT 0.59
- MD 0.43
- MACD
- ADPT 0.03
- MD 0.05
- Stochastic Oscillator
- ADPT 62.45
- MD 47.90
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About MD Pediatrix Medical Group Inc.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.